Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis

The aim of this study was to assess the cost-effectiveness of administering magnesium sulphate to patients in whom preterm birth at

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC health services research 2013-12, Vol.13 (1), p.527-527, Article 527
Hauptverfasser:	Bickford, Celeste D, Magee, Laura A, Mitton, Craig, Kruse, Marie, Synnes, Anne R, Sawchuck, Diane, Basso, Melanie, Senikas, Vyta M, von Dadelszen, Peter
Format:	Artikel
Sprache:	eng
Schlagworte:	Cerebral palsy Cerebral Palsy - economics Cerebral Palsy - prevention & control Children & youth Cost analysis Cost Savings - statistics & numerical data Cost-Benefit Analysis Costs Decision Trees Drug Costs - statistics & numerical data Drug therapy Female Fetus - drug effects Gestational Age Health aspects Health Care Costs - statistics & numerical data Humans Infants (Premature) Life expectancy Magnesium Magnesium sulfate Magnesium Sulfate - economics Magnesium Sulfate - therapeutic use Medical research Medicine Neuroprotective Agents - economics Neuroprotective Agents - therapeutic use Newborn babies Patients Pregnancy Premature babies Premature birth Premature Birth - drug therapy Premature Birth - epidemiology Prenatal Care - economics Prevention Probability Quality of Life Quality-Adjusted Life Years Risk Assessment Studies Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The aim of this study was to assess the cost-effectiveness of administering magnesium sulphate to patients in whom preterm birth at
ISSN:	1472-6963 1472-6963
DOI:	10.1186/1472-6963-13-527